<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105906">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01924962</url>
  </required_header>
  <id_info>
    <org_study_id>BK 1-2011</org_study_id>
    <nct_id>NCT01924962</nct_id>
  </id_info>
  <brief_title>Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries</brief_title>
  <acronym>REVASC</acronym>
  <official_title>A Randomized Comparison of Recanalisation With Implantation of Cypher Sirolimus Eluting Coronary Stents and Medical Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Center Bad Krozingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart Center Bad Krozingen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomised comparison of recanalisation of chronic occluded coronary arteries
      with implantation of Sirolimus eluting stents and medical therapy. Myocardial function and
      scar-size are determinated by using magnetic resonance imaging. The study hypothesis is the
      superiority of medical therapy over revascularisation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the REVASC-study recovery of left ventricular function after recanalization of chronic
      total coronary occlusions (CTO) and implantation of sirolimus-eluting stents will be
      examined and compared to medical treatment. Extent of the scar, viable myocardium in the
      infarct zone and regional left ventricular function will be assessed by cardiac magnetic
      resonance. Patients with regional systolic left ventricular dysfunction of any degree in the
      supply territory of the CTO vessel will be randomized to either recanalization of the
      occluded coronary artery or to conservative therapy. It is of interest whether CTO patients
      will have an improvement in left ventricular function after late coronary reopening,
      regarding the high technical demands and costs of CTO recanalization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes from baseline in regional left ventricular function at 9 months</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure. For regional left ventricular analysis, wall thickening and systolic inward motion will be determined in 12 segments in all short axis slices by the modified centerline method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in global left ventricular function at 9 months</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement of global left ventricular function (assessed by magnetic resonance imaging at baseline and 9 months post-procedure. For global left ventricular analysis, all short-axis slices from the apex to the base will be assessed. By planimetry of all short-axis views, left ventricular end-systolic volume (in milliliters), left ventricular end-diastolic volume (in milliliters), and ejection fraction (in percent) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in left ventricular volume at 9 months</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in diastolic and systolic volume indices (assessed by magnetic resonance imaging at baseline and 9 months post-procedure)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>medical therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>revascularisation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>revascularisation and stent-implantation of chronic occluded coronary artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>revascularisation</intervention_name>
    <description>revascularisation of chronic occluded coronary artery</description>
    <arm_group_label>revascularisation</arm_group_label>
    <other_name>Cypher-stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic total occlusion with thrombolysis in myocardial infarction (TIMI) 0 flow (or
             distal capillary reflow) of a native coronary artery with an estimated reference
             vessel diameter of 2.5 to 4.0 mm

          -  chronic total occlusion has more than 4 weeks duration

          -  the target vessel has not previously been treated with percutaneous coronary
             intervention

          -  the target vessel must be feasible for stent implantation

          -  patient has stable or unstable angina pectoris or a positive functional study for
             ischemia

          -  patient must be 18 years of age or older

          -  female subjects of childbearing age must have a negative pregnancy test within 7 days
             before procedure

          -  patient has been informed of the nature of the study and agrees to its

          -  provisions ans has written informed consent as approved by the Ethics Committee

          -  patient complies with all required post-procedure follow-up

        Exclusion Criteria:

          -  a documented left ventricular function &lt; 30%

          -  patient has a acute myocardial infarction (&gt;3x normal creatine kinase (CK with
             presence of CK-MB) within 72 hours preceding the index procedure and CK has not
             returned to normal limits at the time of the procedure

          -  patients with known hypersensitivity or contraindication to aspirin, heparin,
             clopidogrel, stainless steel or contrast media that cannot be adequately been
             pre-medicated

          -  patient has a platelet count of &lt; 100000 cells/mm3 or &gt; 700000 cells/m3, a white
             blood cell count of &lt; 3000 cells/mm3 or documented or suspected liver disease

          -  patient has a history of bleeding diathesis or coagulopathy

          -  patient has suffered a cerebrovascular accident or transient ischemic attack within
             the past 6 months

          -  active peptic ulcer or upper gastrointestinal bleeding within the prior 6 months

          -  patients has a co-morbidity (i.e. cancer or congestive heart failure) that may cause
             the patient to be non-compliant with the protocol, or is associated with limited
             life-expectancy (less than 2 years)

          -  the target vessel contains intraluminal thrombus

          -  the target vessel or lesson shows angiographic evidence of severe calcification

          -  patient has contraindications to magnetic resonance imaging
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Joachim Buettner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaets-Herzzentrum Freiburg-Bad Krozingen, Clinics for Cardiology and Angiology II, D-79189 Bad Krozingen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universit채ts Herzzentrum Freiburg Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-W체rttemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim B체ttner, MD</last_name>
      <phone>+76334045051</phone>
      <email>achim.buettner@universitaets-herzzentrum.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Gick, MD</last_name>
      <phone>+76334024271</phone>
      <email>michael.gick@universitaets-herzzentrum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Joachim B체ttner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heart Center Bad Krozingen</investigator_affiliation>
    <investigator_full_name>Dr. Heinz Joachim Buettner</investigator_full_name>
    <investigator_title>head of cath-lab department</investigator_title>
  </responsible_party>
  <keyword>chronic occlusion of coronary artery</keyword>
  <keyword>left ventricular function</keyword>
  <keyword>revascularisation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
